Other languages Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.827 ^USD	+0.68%		+0.96%	-26.61%

May. 08	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	CI
May. 08	Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	May. 08
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	Apr. 29
Top Midday Gainers	Apr. 10
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 29
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	Feb. 28
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	Feb. 22
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	Feb. 06
Alterity Dispatches Documents Of Planned Share Sale	Jan. 10
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%	Jan. 07
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan	Dec. 29
Top Premarket Decliners	Dec. 05
Sector Update: Health Care Stocks Rise Late Afternoon	Dec. 04
Sector Update: Health Care	Dec. 04
Top Midday Gainers	Dec. 04
Alterity Therapeutics Shares Surge Pre-Bell as Potential Parkinson's Disease Treatment Yields 'Promising New Data' in Monkeys	Dec. 04
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease	Dec. 04
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy	Nov. 27
Top Premarket Decliners	Nov. 22
Alterity Therapeutics Raises AU$4.8 Million Via Share Placement	Nov. 22
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy	Nov. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Other languages

Filters